Gelteq Limited GELS
Annual
Quarterly
No annual revenue total was found in Gelteq Limited's SEC filings.
Gelteq Limited (GELS) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
$-0.72
Dividend per share
None
Shares outstanding
9.44M
-11.9% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GELS (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- South Melbourne Vic
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1920092
- Former names
- Gelteq Pty Ltd. (until Mar 31, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Jun 30, 2025 |
|---|---|
| Diluted EPS | -$0.72 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Jul 6, 2026 | Jul 2, 2026 |
| 6-K | Current report (foreign issuer) | Jun 30, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jun 2, 2026 |
| 6-K | Current report (foreign issuer) | May 26, 2026 | May 26, 2026 |
| 6-K | Current report (foreign issuer) | Mar 24, 2026 | Mar 24, 2026 |
| 6-K | Current report (foreign issuer) | Dec 9, 2025 | Dec 9, 2025 |
All 72 Gelteq Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.